In a recent meta-analysis [107] including six studies (two RCTS and four single-arm trials) and a total of 723 patients, the authors found that ezetimibe significantly reduced serum aspartate aminotransferase, alanine aminotransferase and Ƴ-glutamyl transpeptidase levels, as well as hepatic steatosis and hepatocyte ballooning. This evidence concerns the gene GPT and fatty liver disease.